Multiple tumor-associated epitopes (MTAE)

Multiple tumor-associated epitopes represent a strategic collection of antigenic determinants derived from proteins that are either uniquely expressed or significantly overexpressed in malignant tissues (National Cancer Institute, 2023). These epitopes, typically short peptide sequences, are presented by Major Histocompatibility Complex (MHC) molecules on the cell surface, allowing them to be recognized by the T-cell receptor (TCR) of CD8+ cytotoxic and CD4+ helper T-cells (Nature Reviews Cancer, 2021). In therapeutic contexts, such as multi-peptide vaccines or adoptive cell therapies, targeting a broad array of epitopes is intended to address the inherent clonal heterogeneity of tumors and minimize the risk of antigen escape, where a tumor evades the immune system by losing a single target (Walter et al., 2012). This multi-target approach is a cornerstone of modern cancer immunotherapy, particularly in the development of off-the-shelf and personalized vaccines for indications like renal cell carcinoma, glioblastoma, and melanoma (Immatics N.V., 2024). Drugs targeting these epitopes work by priming the host's immune system to mount a polyvalent attack against the tumor, often in combination with immune checkpoint inhibitors to enhance efficacy (Science Translational Medicine, 2020).

Other names

Multi-epitopeMulti-antigenTumor-associated antigensTUMAPsMulti-peptide cocktailTumor-associated peptides

Induction of a polyvalent T-cell mediated immune response (CD8+ and CD4+) against multiple tumor antigens simultaneously to prevent immune escape and address tumor heterogeneity (Walter et al., 2012; Immatics N.V., 2024).